Portal de Periódicos da CAPES

Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study

2001; Wiley; Volume: 8; Issue: 3 Linguagem: Inglês

10.1046/j.1468-1331.2001.00218.x

1468-1331

K. Gruffyd‐Jones, Bryan Kies, Anna Middleton, L. J. M. M. Mulder, Øyvind Røsjø, David Millson,

Sympathectomy and Hyperhidrosis Treatments

This randomized, double‐blind, parallel‐group study compared the efficacy and tolerability of zolmitriptan (2.5 or 5 mg) and sumatriptan (50 mg) in the acute oral treatment of up to six moderate‐to‐severe migraine attacks. The intention to treat (ITT) population comprised of 1522 patients: 500 treated with zolmitriptan 2.5 mg (2671 attacks), 514 with zolmitriptan 5 mg (2744 attacks) and 508 with sumatriptan 50 mg (2693 attacks). Overall, the 2‐h headache response rates in these groups were 62.9, 65.7 and 66.6%, respectively. There were no statistically significant differences between sumatriptan 50 mg and zolmitriptan 2.5 mg ( P =0.12) or 5 mg ( P =0.80). Approximately 40% of patients in each group reported a 2‐h headache response in ≥ 80% of attacks. There were no statistically significant differences between the groups in the rates of headache response at 1 h (zolmitriptan 2.5 mg 36.9%, zolmitriptan 5 mg 39.5% and sumatriptan 50 mg 38.0%) or 4 h (70.3, 72.9 and 72.2%, respectively) or in the rates of meaningful migraine relief at 1, 2 or 4 h or sustained (24‐h) pain relief. All treatments were well tolerated. In conclusion, zolmitriptan (2.5 or 5 mg) proved similarly efficacious compared with sumatriptan (50 mg), both in terms of response rates and consistency across attacks.